Imagine a world where we could significantly reduce the heartache of preterm births, a global issue affecting millions of families. But here's where it gets controversial: could something as simple as omega-3 fatty acids hold the key? Researchers at SAHMRI (South Australian Health and Medical Research Institute) believe so, and their groundbreaking work is poised to revolutionize antenatal care worldwide.
In a recent study published in the Medical Journal of Australia—coinciding with World Prematurity Day—SAHMRI’s Omega-3 Test-and-Treat Program (O3TTP) has proven to be a game-changer. This program, seamlessly integrated into routine care in South Australia, not only demonstrates feasibility and scalability but also shows promising results in preventing preterm births. And this is the part most people miss: it’s as simple as a blood test and, if needed, a supplement recommendation.
Dr. Karen Best, the program’s leader, presented these findings at the Australian Clinical Trials Association symposium in Melbourne. She highlighted that hundreds of South Australian mothers have already benefited from tailored omega-3 supplementation, reducing their risk of preterm birth. “What’s truly remarkable,” Dr. Best noted, “is the global interest we’ve seen, from Australia to the U.S. and Europe. With these peer-reviewed findings, we expect the world to take notice of this proven intervention.”
Take Amy Christie, a first-time mom-to-be from South Australia, who was 35 weeks pregnant when she learned about the program. “I always thought I was healthy, but I had no idea low omega-3 levels could increase the risk of preterm birth,” she shared. After a routine blood test, Amy discovered her levels were low and started supplementation. “I’m so grateful I had that conversation with my midwife. It could have made all the difference for my baby.”
Here’s the eye-opening statistic: of the thousands of South Australian women tested, 17% had low omega-3 levels, meaning they could benefit from supplementation. Dr. Best emphasized, “That’s hundreds of families who’ve improved their chances of a full-term birth, all thanks to this research.”
Preterm birth remains a stubborn global challenge, with about 1 in 12 babies born too early. These babies often face lengthy hospital stays and long-term health issues, from respiratory problems to developmental delays. Boldly put, preterm birth complications are the leading cause of death for children under five worldwide. Yet, the O3TTP offers a ray of hope by addressing a preventable risk factor.
The program, a collaboration between SAHMRI and SA Pathology, integrates omega-3 blood screening into the standard South Australian Maternal Serum Antenatal Screening (SAMSAS) test. This final stage caps over a decade of research into how omega-3 supplementation can prevent preterm births. “The beauty of this program,” Dr. Best explained, “is its simplicity. No extra blood tests—just a tick-box on the SAMSAS form.”
During the initial 14-month phase (April 2021–June 2022), 4,801 women were tested. Since then, over 30,000 women have undergone screening, with 17% identified as having low omega-3 levels. “With accurate omega-3 measurements, we can recommend targeted supplementation to reduce preterm birth risks,” Dr. Best said. “Our goal now is to expand this across Australia and beyond.”
But here’s the controversial question: If omega-3 supplementation is so effective, why isn’t it already a global standard in antenatal care? Could it be oversight, cost, or simply lack of awareness? We’d love to hear your thoughts in the comments.
For more details, check out the full study by Dr. Karen Best et al. in the Medical Journal of Australia (DOI: 10.5694/mja2.70101). Together, we can spark conversations that could save lives and transform maternal care.
